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OBJECTIVE—Cannabinoid type 1 (CB1) receptor is involved in
whole-body and cellular energy metabolism. We asked whether
CB1 receptor stimulation was able to decrease mitochondrial
biogenesis in different metabolically active tissues of obese
high-fat diet (HFD)-fed mice.
RESEARCH DESIGN AND METHODS—The effects of selec-
tive CB1 agonist arachidonyl-2-chloroethanolamide (ACEA) and
endocannabinoids anandamide and 2-arachidonoylglycerol on
endothelial nitric oxide synthase (eNOS) expression were exam-
ined, as were mitochondrial DNA amount and mitochondrial
biogenesis parameters in cultured mouse and human white
adipocytes. These parameters were also investigated in white
adipose tissue (WAT), muscle, and liver of mice chronically
treated with ACEA. Moreover, p38 mitogen-activated protein
kinase (MAPK) phosphorylation was investigated in WAT and
isolated mature adipocytes from eNOS
/ and wild-type mice.
eNOS, p38 MAPK, adenosine monophosphate–activated protein
kinase (AMPK), and mitochondrial biogenesis were investigated
in WAT, muscle, and liver of HFD mice chronically treated with
ACEA.
RESULTS—ACEA decreased mitochondrial biogenesis and
eNOS expression, activated p38 MAPK, and reduced AMPK
phosphorylation in white adipocytes. The ACEA effects on mito-
chondria were antagonized by nitric oxide donors and by p38
MAPK silencing. White adipocytes from eNOS
/ mice displayed
higher p38 MAPK phosphorylation than wild-type animals under
basal conditions, and ACEA was ineffective in cells lacking
eNOS. Moreover, mitochondrial biogenesis was downregulated,
while p38 MAPK phosphorylation was increased and AMPK
phosphorylation was decreased in WAT, muscle, and liver of
ACEA-treated mice on a HFD.
CONCLUSIONS—CB1 receptor stimulation decreases mito-
chondrial biogenesis in white adipocytes, through eNOS down-
regulation and p38 MAPK activation, and impairs mitochondrial
function in metabolically active tissues of dietary obese mice.
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T
he expansion of body fat, and particularly of
visceral fat, in obese individuals is linked to
increased cardiovascular risk. Recent studies
have demonstrated that mitochondrial biogene-
sis and function are decreased in white adipose tissue
(WAT), liver, and skeletal muscle of obese/diabetic ani-
mals and humans (1). Notably, nitric oxide (NO) generated
by endothelial NO synthase (eNOS) increases mitochon-
drial biogenesis, including peroxisome proliferator–
activated receptor  coactivator-1 (PGC-1) gene ex-
pression, in white adipocytes and myocytes (2,3), while
genetic eNOS deletion downregulates mitochondrial bio-
genesis (2,3). Interestingly, eNOS deletion increases p38
mitogen-activated protein kinase (MAPK) activity (4),
which can reduce PGC-1 and mitochondrial gene expres-
sion (5). On the other hand, the metabolic sensor adeno-
sine monophosphate–activated protein kinase (AMPK)
activates eNOS (6), PGC-1 expression, and mitochondrial
biogenesis (7).
Cannabinoid type 1 (CB1) receptors control energy
metabolism through the modulation of many central and
peripheral processes (8). Notably, CB1 receptor–deﬁcient
mice are lean (9) and resistant to a high-fat diet (HFD)
(10). Similarly, the selective CB1 receptor antagonist
SR141716 (rimonabant) persistently reduces body weight
of obese mice (11), improving WAT metabolism with
reversion of liver steatosis (12) and increasing glucose
uptake in skeletal muscle (13). We have recently demon-
strated that both genetic and pharmacological blockade of
CB1 receptor increases AMPK activity, mitochondrial
biogenesis and function in WAT of HFD-fed mice, in an
eNOS-dependent manner, to the levels of chow regular
diet-fed controls (14). This is accompanied by a reduced
body weight gain and adiposity.
Since the endocannabinoid system is overactive in pe-
ripheral organs, and particularly in the visceral fat of
obese subjects, while circulating levels of endocannabi-
noids are elevated in type 2 diabetic patients (15), our
previous results suggested that the CB1 receptor over-
stimulation, by downregulating mitochondrial biogenesis
in metabolically active tissues, could partly justify the
increased fat depots and metabolic dysfunctions in obese
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effects of endocannabinoid receptor agonists, including
2-arachidonoyl-glycerol (2-AG) and anandamide (AEA),
and selective CB1 agonist, such as arachidonyl-2-chloro-
ethanolamide (ACEA) (16), on mitochondrial biogenesis in
primary white adipocytes and WAT, liver, and skeletal
muscle of lean and obese mice. Moreover, the role of
eNOS, p38 MAPK, and AMPK pathways in this process was
investigated.
RESEARCH DESIGN AND METHODS
Cell culture and reagents. White fat precursor cells were enzymatically
isolated from epididymal WAT of 8-week-old male C57BL/6J, wild-type (F2
hybrid B6.129S2 obtained from crossing C57BL/6J and 129S1/SvImJ mice), and
B6.129P2-Nos3
tm1Unc/J (eNOS
/) mice (17) (The Jackson Laboratories, Bar
Harbor, ME) and cultured as previously described (14). At day 3–4 from
seeding, cells were exposed to the culture medium containing CB1 agonists
for 48 h or different periods of time when speciﬁed. The medium was
discarded, the wells were washed twice with 2 ml ice-cold phosphate-buffered
solution (PBS) (Sigma-Aldrich), and the cells were harvested as reported
below for the different assays. Primary human subcutaneous and visceral
preadipocytes, isolated from subcutaneous and visceral/abdominal tissue
(kidney and bladder) of normal weight subjects without metabolic disorders,
together with speciﬁc growth media, were purchased from Lonza (Walkers-
ville, MD). SB203580 and SB202190 were obtained from Tocris Bioscience
(Bristol, U.K.). All other chemicals, including ACEA, 2AG, and AEA, were
purchased from Sigma (Milan, Italy).
CB1 siRNA and p38MAPK siRNA. White adipocytes were transfected at day
3–4 after seeding with 10 nmol/l CB1 or 50 nmol/l p38MAPK siRNA SMART-
pool (Dharmacon, Lafayette, CO) or siCONTROL nontargeting siRNA using
Dharmafect three transfection reagent. Cells were treated for 48 h with 0.01
mol/l ACEA, and RNA and protein were harvested. Efﬁcacy of transfection
was determined using siGLO-RISC-free nontargeting siRNA and estimation of
siRNA uptake by ﬂuorescence detection (absorbance/emission 557/570 nm).
Animals and treatments. The animals were treated according to protocols
approved by the Milan University Institutional Animal Care and Use Commit-
tee. In particular, 8-week-old (n  20) male wild-type and eNOS
/ mice (17)
were housed four per cage. Moreover, 4-week-old male C57BL/6J mice (Harlan
Nossan) were fed either a chow regular diet (Chow) (8 kcal % fat, 19 kcal %
protein, 73 kcal % carbohydrate) or a high-fat diet (HFD) (45 kcal % fat, 20 kcal
% protein, and 35 kcal % carbohydrate, D12451; Research Diets, New Bruns-
wick, NJ) for 6 weeks before treatments. While fed on chow or a HFD, these
mice (n  10 per group) were further treated with either vehicle or ACEA (at
2.5 mg/kg i.p.) for 4 weeks. To avoid potential habituation, ACEA doses were
increased through time as treatment advanced as follows: 1.25 mg/kg on days
1–3, 1.9 mg/kg on days 4–6, and 2.5 mg/kg for the rest of treatment (18). Mice
did not display signs of catalepsy (as frozen postures or immobility) (data not
shown). Body weight and food intake were recorded weekly. Adiposity (wet
weight of visceral and subcutaneous fat), cumulative food intake (for the time
of the experiment), and feed efﬁciency were measured (2). On the day of the
experiments, animals were killed by cervical dislocation and epididymal WAT
was immediately isolated, frozen in liquid nitrogen, and stored at 80°C
before processing for mRNA, protein, and citrate synthase analysis.
Isolation of mouse mature adipocytes. Wild-type and eNOS
/ mice, both
on the chow regular diet (n  6 per group), were killed, and epididymal WAT
was excised. Fat pads from two mice were pooled, and mature adipocytes
were acutely isolated in Hank’s balanced salt solution (HBSS) containing 4%
bovine serum albumin (BSA) and 1.5 mg/ml collagenase (Calbiochem) as
previously described (19).
RNA analysis. Quantitative RT-PCR reactions were performed as previously
described (14) and run with the iQ SybrGreenI SuperMix (Bio-Rad) on an
iCycler iQ Real Time PCR detection system (Bio-Rad). Calculations were
performed by a comparative method (2
Ct) using 18S rRNA as an internal
control. Primers were designed using Beacon Designer 2.6 software (Premier
Biosoft International).
Immunoblot analysis. Protein extracts were analyzed by immunoblotting as
previously described (14). Protein extracts were obtained by harvesting
cultured adipocytes in M-PER Mammalian Protein Extraction Reagent as
indicated by the manufacturer in the presence of 1 mmol/l NaVO4, 10 mmol/l
NaF, and a cocktail of protease inhibitors (Sigma-Aldrich). Protein content
was determined by the bicinchoninic acid protein assay (Pierce), and 50 g
proteins were run on SDS-PAGE under reducing conditions. The separated
proteins were then electrophoretically transferred to a nitrocellulose mem-
brane (Pierce). Proteins of interest were revealed with speciﬁc antibodies:
anti-eNOS (Transduction Labs), anti–cytochrome c oxidase IV (COX IV)
(Molecular Probes), and anti–cytochrome c (Cyt c) (BD Bioscience), each at
1:500 dilution; anti–phospho–p38 MAPK (Thr180/Tyr182) and anti–p38 MAPK
(both at 1:1,000 dilution; Cell Signaling Technology); anti–phospho–AMPK
(Thr172) and anti–AMPK (both at 1:1,000 dilution; Cell Signaling Technol-
ogy); and anti–-actin (1:10,000; Sigma-Aldrich). The immunostaining was
detected using horseradish peroxidase–conjugated anti-rabbit or anti-mouse
immunoglobulin for1ha troom temperature. After the visualization of
phospho–p38 MAPK or phospho-AMPK, ﬁlters were stripped with the
Re-Blot Western blot recycling kit (Chemicon International) and further used
for the visualization of total p38 MAPK or AMPK. Bands were revealed by the
SuperSignal Substrate (Pierce) and quantitated by densitometry using a Quick
Image densitometer (Canberra Packard) and a Phoretix 1D, version 3.0,
software image analyser.
Mitochondrial DNA. Mitochondrial DNA copy number was measured by
means of quantitative PCR from the cytochrome C oxidase II mtDNA gene
compared with the UCP2 nuclear gene in tissues of ACEA-treated mice and
wild-type mice fed either chow or a HFD as previously described (14).
Oxygen consumption. White adipocytes were harvested by trypsinization,
centrifuged at 500g for 5 min at 4°C, and resuspended in HBSS. Cell samples
(4  10
6/ml) were analyzed at 37°C in a gas-tight vessel equipped with a
Clark-type oxygen electrode (Rank Brothers) connected to a chart recorder.
Cellular oxygen consumption was measured as previously described (14). The
oxygen electrode was calibrated, assuming the concentration of oxygen in the
incubation medium at 37°C to be 200 mol/l. Protein content in both cell and
tissue samples was determined by the bicinchoninic acid protein assay
(Pierce).
Mitochondrial mass. White adipocytes seeded onto glass coverslips were
incubated with medium containing 200 nmol/l Mitotracker red 580 (Invitro-
gen). After incubation for 30 min at 37°C, coverslips were rinsed two times
with medium and two times with PBS and ﬁxed at room temperature for 10
min in 4% paraformaldehyde in PBS. Coverslips were mounted onto glass
slides and were then observed with a Bio-Rad confocal microscope MRC1024.
Citrate synthase activity and statistical methods. The activity was
measured spectrophotometrically at 412 nm at 30°C in either tisssue or whole
cell extracts (14). Tissue or cell homogenates were added to buffer containing
0.1 mmol/l 5,5-dithio-bis-(2-nitrobenzoic) acid, 0.5 mmol/l oxaloacetate, 50
mol/l EDTA, 0.31 mmol/l acetyl CoA, 5 mmol/l triethanolamine hydrochlo-
ride, and 0.1 mol/l Tris-HCl, pH 8.1. Citrate synthase activity was expressed as
nanomoles citrate produced per minute per milligram of protein or relative
values. Raw data from each experiment were analyzed using either ANOVA
with Newman-Keuls’ multiple comparison post hoc test or t test.
RESULTS
ACEA decreases mitochondrial biogenesis in mouse
white adipocytes. CB1 receptor stimulation by ACEA,
AEA, and 2-AG downregulated mitochondrial biogenesis
in a reversed concentration-dependent manner in cultured
mouse white adipocytes (Fig. 1 and supplementary Fig. 1,
available in the online appendix [http://diabetes.
diabetesjournals.org/cgi/content/full/db09-1881/DC1]). In
particular, the effects of ACEA, tested on several mito-
chondrial markers, were most evident at 0.01 mol/l, with
higher concentrations being less effective (Fig. 1) and
lower concentrations (0.01–1.0 nmol/l) lacking efﬁcacy
(supplementary Fig. 2). The mRNA levels of PGC-1,
nuclear respiratory factor-1 (NRF-1), and mitochondrial
DNA transcription factor A (Tfam) (three key regulators of
mitochondrial biogenesis) (20), as well as the mtDNA
amount, were lower in ACEA- than in vehicle-treated cells
(Fig. 1A and B). Protein levels of COX IV and Cyt c (two
mitochondrial proteins involved in oxidative phosphoryla-
tion) (Fig. 1C), activity of citrate synthase (Fig. 1D), and
oxygen consumption (Fig. 1E) were decreased by the CB1
receptor stimulation. Furthemore, white adipocytes
treated with ACEA showed a signiﬁcant decrease of
MitoTracker Red signal, indicating the decrease of mito-
chondrial mass compared with vehicle-treated cells (Fig.
1F). Similar results were obtained with AEA and 2-AG
(supplementary Fig. 1).
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subcutaneous and visceral white adipocytes. CB1 re-
ceptor stimulation by ACEA downregulated mitochondrial
biogenesis in cultured subcutaneous and visceral white
adipocytes of normal-weight subjects. A signiﬁcant reduc-
tion of PGC-1, NRF-1, and Tfam mRNA levels was
observed in subcutaneous and visceral white adipocytes
exposed for 2 days to 0.01 mol/l ACEA (supplementary
Fig. 3A). Similarly, the mtDNA amount, COX IV and Cyt c
protein levels, citrate synthase activity, and oxygen con-
sumption were decreased by the CB1 receptor stimulation
(supplementary Fig. 3B–E). All of these effects were dose
dependent, with maximal effect at 0.01 mol/l ACEA (data
not shown). Although the expression of CB1 receptor was
reported to be higher in the subcutaneous than in the
visceral fat of lean subjects (21), no relevant difference in
the ACEA effects on mitochondrial biogenesis were seen
between human subcutaneous and visceral adipocytes.
Further analysis will be necessary to clarify this point.
NO-generating pathway is involved in ACEA effects
on mitochondrial biogenesis. Given that eNOS stimula-
tion was reported to increase mitochondrial biogenesis in
WAT cells (2) and that CB1 receptor blockade promotes
mitochondrial biogenesis by upregulating eNOS (14), we
hypothesized that the inhibitory effects of CB1 agonists on
mitochondrial biogenesis could be due to downregulation
of eNOS expression and NO production. ACEA signiﬁ-
cantly decreased eNOS mRNA (Fig. 2A) and protein levels
(Fig. 2B) in primary mouse white adipocytes. To verify
that the downregulation of eNOS by ACEA is a relevant
molecular mechanism by which mitochondrial biogenesis
is affected, mouse fat cells were treated with 0.01 mol/l
ACEA in the presence of two structurally unrelated NO
donors. (Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]-
diazen-1-ium-1,2-diolate] (DETA-NO) (50 mol/l) pre-
vented the effect of ACEA on mitochondrial biogenesis
with a full restoration of PGC-1, NRF-1, Tfam, COX IV,
and Cyt c expression and mtDNA amount in fat cells (Fig.
2C and D). Similar results were obtained with 100 mol/l
S-nitroso-acetyl penicillamine (SNAP) (data not shown).
ACEA affects mitochondrial biogenesis through CB1
receptor stimulation. Prolonged exposure of white adi-
pocytes to different concentrations of ACEA did not
modify CB1 receptor mRNA levels (supplementary Fig.
4A). CB2 mRNA levels were decreased by ACEA treatment
(supplementary Fig. 4B). Because CB1 agonists induce
adipocyte differentiation (15,22), the latter result may
reﬂect the reduction of CB2 receptors that accompanies
adipocyte differentiation (22). To assess the CB1 receptor
dependence of ACEA effects on eNOS expression and
mitochondrial biogenesis, primary white adipocytes were
transfected with small interference RNA (siRNA) against
CB1 receptor or nontargeting siRNA as a negative control.
We veriﬁed that CB1 siRNA reduced CB1 receptor mRNA
levels by 85% (Fig. 3A). While white adipocytes treated
with 0.01 mol/l ACEA showed decreased eNOS mRNA,
CB1 receptor knockdown reduced the inhibitory effects of
ACEA with a partial, albeit statistically signiﬁcant, recov-
ery of eNOS expression (Fig. 3B). Accordingly, a partial
recovery of mitochondrial gene expression, mtDNA
amount, and citrate synthase activity was observed (Fig.
3C–E). Importantly, the CB1 silencing per se did not
modify any mitochondrial biogenesis parameters. Thus,
our present results suggest that the effects of ACEA on
eNOS expression and mitochondrial biogenesis are at least
in part mediated by the CB1 receptors in white adipocytes.
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FIG. 1. The CB1 receptor agonist ACEA decreases mitochondrial biogenesis in cultured mouse white adipocytes. A: PGC-1, NRF-1, and Tfam
mRNA levels were analyzed by means of quantitative RT-PCR in white adipocytes treated either with vehicle (0.002% DMSO) (Veh) or different
doses of ACEA for 2 days. Relative expression values of the vehicle-treated cells were taken as 1.0 (n  5 experiments; *P < 0.05 and **P < 0.01
vs. vehicle-treated cells). B: mtDNA amount, analyzed by means of quantitative PCR and expressed as mtDNA copy number per nuclear DNA copy
number. *P < 0.05 and **P < 0.01 vs. vehicle-treated cells. C: COX IV and Cyt c proteins were detected by immunoblot analysis (one experiment
representative of ﬁve reproducible ones). Numbers below the blots are values of densitometric analysis referring to -actin. D and E: Citrate
synthase activity (nmol citrate  min
1  mg
1 protein) (D) oxygen consumption (nmol O2  min
1  mg
1 protein) (E) were expressed as fold
change vs. vehicle-treated cells taken as 1.0 (n  3 experiments; *P < 0.05 and **P < 0.01 vs. vehicle-treated cells). All data represent means 
SEM. F: Mitochondrial mass in white fat cells visualized as MitoTracker Red signal by confocal microscopy. Images were acquired by using a 40
objective. (A high-quality color representation of this ﬁgure is available in the online issue.)
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another reported target of low concentrations (in micro-
moles) of ACEA, i.e., the transient receptor potential
vanilloid subfamily type 1 (TRPV1) (23). This receptor is
expressed in preadipocytes and at a lower amount also in
adipocytes (24), where its activation reduces lipogenesis,
possibly exerting effects opposite to those of CB1 stimu-
lation (24). Primary white adipocytes were transfected
with siRNA against TRPV1 receptor or nontargeting siRNA
as a negative control. We veriﬁed that TRPV1 siRNA
reduced TRPV1 receptor mRNA levels by 80% (supple-
mentary Fig. 5). Notably, TRPV1 receptor knockdown
left unchanged the inhibitory effects of 0.01 mol/l
ACEA on eNOS and mitochondrial gene expression,
mtDNA amount, and citrate synthase activity (supple-
mentary Fig. 5).
ACEA induces p38 MAPK activation via eNOS down-
regulation. Increasing evidence suggests that a link exists
between NO/eNOS and p38 MAPK activity in various cell
types (4,25). In particular, p38 MAPK phosphorylation is
increased in ventricular cardiomyocytes of eNOS knock-
out mice (4). Actually, we found that p38 MAPK phosphor-
ylation was 90 	 4% higher in WAT of eNOS
/ compared
with littermate control mice (Fig. 4A).
Because WAT contains different cell types besides adi-
pocytes, mature white adipocytes were acutely isolated
from epididymal fat pad of eNOS
/ and wild-type litter-
mates on the chow regular diet. Again, isolated adipocytes
with eNOS gene deletion showed strongly increased p38
MAPK phosphorylation (Fig. 4B). CB1 receptor stimula-
tion can activate p38 MAPK (26). Treatment of cultured
white adipocytes with 0.01 mol/l ACEA increased p38
MAPK phosphorylation within 30 min, and this effect
persisted until 24 h (representative data are shown at 1 h
[Fig. 4C]). Further, primary white adipocytes from
eNOS
/ mice showed increased phospho–p38 MAPK
protein compared with primary adipocytes from wild-type
mice (Fig. 4D). Interestingly, ACEA (0.01 mol/l for 1–16
h) was unable to increase p38 MAPK phosphorylation in
primary white adipocytes obtained from eNOS
/ knock-
out unlike that from wild-type mice (Fig. 4D), suggesting
that p38 MAPK activation by ACEA occurs via eNOS
downregulation. Accordingly, ACEA was ineffective at
further decreasing the impaired mitochondrial biogenesis
in white adipocytes lacking eNOS (data not shown).
ACEA affects mitochondrial biogenesis through p38
MAPK activation. Because p38 MAPK activation has
been reported to decrease PGC-1 expression in C2C12
cells (5), we investigated whether p38 MAPK was involved
in mitochondrial biogenesis downregulation by ACEA.
Treatment with p38 MAPK inhibitors SB203580 and
SB202190 prevented the 0.01 mol/l ACEA-induced de-
creases in PGC-1, NRF-1, and Tfam mRNA levels (Fig.
5A), mtDNA amount (Fig. 5B), and citrate synthase activ-
ity (Fig. 5C).
Because pharmacological inhibitors are often nonspe-
ciﬁc, white adipocytes were transfected with siRNA di-
rected against p38 MAPK or nontargeting siRNA as a
negative control. The p38 MAPK mRNA levels were re-
duced by 75 	 3% (Fig. 5D), while the p38 MAPK protein
levels were reduced by 60 	 3% (Fig. 5E)i np 3 8  MAPK
siRNA-treated cells. Importantly, the p38 MAPK silencing
prevented the 0.01 mol/l ACEA-mediated downregulation
of PGC-1, NRF1, and Tfam (Fig. 5F) and the reduction of
mtDNA amount (Fig. 5G), conﬁrming a mechanistic role
for the p38 MAPK-dependent pathways in mediating the
effects of ACEA on mitochondrial biogenesis in fat cells.
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strated that CB1 receptor blockade increased AMPK phos-
phorylation and activity in cultured white adipocytes (14).
Since the AMPK cascade has been described to activate
eNOS and NO production (6), we hypothesized that AMPK
might be involved in the effect of CB1 receptor stimulation
on mitochondrial biogenesis. In fact, treatment of cultured
white adipocytes with 0.01 mol/l ACEA reduced AMPK
phosphorylation (supplementary Fig. 6).
CB1 receptor agonist downregulates mitochondrial
biogenesis in metabolically active tissues and in-
creases body weight in obese mice. To assess whether
the cannabinoid receptor stimulation decreases mitochon-
drial biogenesis in vivo, we examined the eNOS expres-
sion and markers of mitochondrial biogenesis in
epididymal fat pads, tibialis muscle, and liver derived from
male mice on either the chow regular diet or HFD for 6
weeks and then treated with ACEA (2.5 mg  kg
1  day
1
i.p.) (16,18) or vehicle for 4 weeks. No effect was seen in
chow regular diet–fed mice (Fig. 6 and supplementary
Figs. 7 and 8). As expected (27), HFD reduced eNOS
expression and mitochondrial biogenesis in WAT of un-
treated mice (Fig. 6). This effect was observed also in
muscle and liver (supplementary Figs. 7 and 8). Although
eNOS expression was unchanged in WAT (Fig. 6A), it was
decreased in muscle and liver (supplementary Figs. 7A and
8A), and the mRNA levels of PGC-1, NRF-1, and Tfam and
the mtDNA amount were lower in WAT (Fig. 6B and C),
muscle (supplementary Fig. 7B and C), and liver (supple-
mentary Fig. 8B and C) of ACEA-treated HFD mice than in
those of vehicle-treated HFD mice. Also, COX IV and Cyt c
protein levels and citrate synthase activity were lower in
WAT (Fig. 6D and E), muscle (supplementary Fig. 7D and
E), and liver (supplementary Fig. 8D and E) of ACEA-
treated HFD mice than in those of vehicle-treated HFD
mice. Further, ACEA treatment increased p38 MAPK phos-
phorylation in WAT, muscle, and liver of HFD mice (Fig.
6F and supplementary Figs. 7F and 8F). We previously
found that AMPK activity was reduced in WAT of HFD-fed
mice (14). Noticeably, ACEA treatment decreased AMPK
phosphorylation in WAT (Fig. 6G), muscle (supplementary
Fig. 7G), and liver (supplementary Fig. 8G) of HFD mice.
Interestingly, unlike chow regular diet–fed mice, the
mean body weight and adiposity of the ACEA-treated mice
were higher compared with those of the vehicle-treated
mice on the HFD (Fig. 7A and B). Cumulative food intake
was comparable between the two groups (Fig. 7C), al-
though ACEA-treated mice showed a greater feed efﬁ-
ciency than their vehicle-treated controls (Fig. 7D). These
results suggest that a CB1 receptor stimulation may impair
the oxidative metabolism in WAT, muscle, and liver and
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obese animals on a HFD.
DISCUSSION
We have previously demonstrated that both genetic (CB1
knockout mice) and pharmacological (SR141716-treated
mice) blockade of the cannabinoid CB1 receptor increases
mitochondrial biogenesis in an eNOS-dependent manner
and enhances AMPK activity in white adipocytes and WAT
(14), possibly antagonizing an endocannabinoid tone
present in cultured fat cells and in fat. The present study
clearly demonstrates that ACEA and endocannabinoid
receptor agonists downregulate mitochondrial biogenesis
and function in mouse and human primary white adipo-
cytes. In particular, the expression of PGC-1, which
coordinately regulates the entire mitochondrial biogenesis
program (20), was markedly and concentration-depen-
dently decreased by the cannabinoid agonists. Mitochon-
drial mass and function were decreased as well.
Notably, the CB1 receptor stimulation decreases mito-
chondrial biogenesis in metabolically active tissues, in-
cluding WAT, muscle, and liver, in vivo. Four week
treatment with ACEA, at a concentration that does not
impair locomotor activity or induce evident side effects
(18), reduced mitochondrial biogenesis in obese mice (i.e.,
HFD-fed mice). Although food intake was comparable
between the two groups, feed efﬁciency was higher in the
ACEA-treated than in the vehicle-treated obese mice,
suggesting that the whole-body oxidative metabolism is
decreased in the drug-treated animals. Accordingly, the
body weight and adiposity of treated obese mice were
higher compared with those of the vehicle-treated obese
animals. On the contrary, ACEA was ineffective in chow
regular diet–fed mice. In line with previous reports (28),
food intake measured 1–3 h after the ﬁrst ACEA adminis-
tration was transiently increased in both lean and HFD
mice (data not shown). A few hypotheses may be offered
to explain the lack of ACEA effects in lean mice after
chronic treatment. Since cannabinoid/CB1 signaling is
overactive in the peripheral tissues of HFD mice, including
WAT (15,22), it is possible that ACEA only worked in these
mice as a result of additive effects with the enhanced
endogenous tone. Furthermore, like AEA, ACEA is de-
graded by the enzyme fatty acid amide hydrolase (FAAH),
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and shows reduced activity in the liver of HFD mice (30)
compared with lean controls. Thus, it is possible that
ACEA could undergo enhanced FAAH degradation in lean
mice. Further, differences have been found in FAAH
expression between visceral and subcutaneous WAT of
HFD mice, possibly contributing to the observation that
while the endocannabinoid system is overactive in visceral
fat, it seems to be hypoactive in the subcutaneous adipose
tissue (22,31). Further work will be required to clarify this
complex point.
Multiple lines of evidence support the hypothesis that
mitochondrial dysfunction is a key feature of obesity,
insulin resistance, and type 2 diabetes (1,27) and may
contribute to reduced lipid oxidation and accumulation of
adipose and/or intramyocellular lipids (32). Moreover, a
key role of endocannabinoids in the regulation of energy
homeostasis, at both the central and peripheral levels, has
been suggested (8,33). In particular, the endocannabinoids
have emerged as an important link between cell energy
metabolism and obesity, insulin resistance, and type 2
diabetes (34). Elevated circulating and adipose endocan-
nabinoid levels in obese and type 2 diabetic subjects
correlate with insulin resistance (35). Moreover, the infu-
sion of cannabinoid receptor agonists in both rodents and
humans induces insulin resistance in liver, muscle, and
adipose tissue (36) and inhibits the respiratory enzyme
activity of different rodent tissues (brain, liver, skeletal
muscle, and heart) (37), with a reduction of the oxygen
consumption rates (38). Here, we demonstrated that en-
docannabinoids and ACEA decrease several mitochondrial
biogenesis markers, including PGC-1 expression, and
reduce mitochondrial function in different metabolically
active tissues. Our previous studies showed that PGC-1
expression was reduced in WAT from mice with either
genetic or diet-induced obesity (27)—a result recently
strenghtened by the observation that adipose expression
of PGC-1 and mitochondrial genes is decreased in obese
compared with nonobese cotwins (39).
Notably, while CB1 receptor expression increases with
adipocyte differentiation (15,22), CB1 receptor stimulation
increases adipogenesis (15,22). Our results with ACEA
suggest that the CB1 receptor may be involved in adipose
mitochondrial biogenesis downregulation. Nonetheless, a
robust knockdown of the CB1 receptor did not completely
reduce the inhibitory effects of ACEA on eNOS expression
and mitochondrial biogenesis. Although ACEA is de-
scribed as a selective CB1 receptor agonist (16), one
cannot exclude that either CB2 receptor or cannabinoid
receptor–independent signaling pathways may be partly
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biogenesis by ACEA. CB2 receptors were downregulated
by prolonged exposure to ACEA, although this may be
linked to the CB1-induced adipocyte differentiation (40),
which is accompanied by CB2 downregulation (22,40).
Moreover, the present results argue against the involve-
ment of TRPV1, which can be stimulated by ACEA (23)
and is expressed in low amounts in adipocytes (24). The
TRPV1 activation would have been able to explain the
reversed concentration-response curve of ACEA. Although
CB1 receptor downregulation may not be ruled out, the
reason for such a behavior remains an open question. On
the other hand, endocannabinoids, such as AEA and 2-AG,
are produced upon demand through the hydrolysis of
precursor N-arachidonoyl-phosphatidylethanolamine (16)
and may be taken up into the cells by simple diffusion or
through speciﬁc membrane transporter (41). Intriguingly,
endocannabinoids and synthetic cannabinoids may bind to
transcription factors (i.e., PPAR-) (42) or cause changes
in integrated mitochondrial function, directly, in the ab-
sence of cannabinoid receptors (43).
Our present ﬁndings strongly suggest that the mitochon-
drial biogenesis deﬁcit induced by ACEA is a consequence
of a deﬁcit in the NO-generating system. Not only does
ACEA downregulate eNOS expression but NO donors are
able to counteract the ACEA effects on mitochondrial
biogenesis in white adipocytes. Previous studies have
shown that NO stimulates cellular AEA uptake and degra-
dation (44). Therefore, based on the present results, there
might be a vicious circle through which ACEA, by reduc-
ing NO production, prevents its own degradation (as well
as that of endogenous cannabinoids), thus possibly ampli-
fying its own effects, especially in HFD mice, where eNOS
expression is reduced.
Although NO has been shown to increase p38 MAPK
activity in endothelial cells (25), other groups have re-
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in cardiomyocytes (4). We now demonstrate that sus-
tained activation of p38 MAPK by ACEA occurs in parallel
with reductions in eNOS and PGC-1. Moreover, using 1)
two inhibitors of p38 MAPK activity, and 2) siRNA-medi-
ated reduction in p38 MAPK expression, we show that
p38 MAPK can mediate ACEA-induced decreases in mito-
chondrial biogenesis parameters, including PGC-1 ex-
pression. Interestingly, our data are in line with a recent
study demonstrating that activation of p38 MAPK contrib-
uted to palmitate-mediated reduction of PGC-1 in skele-
tal muscle cells (5). We show here that p38 MAPK
phosphorylation is increased by ACEA treatment in WAT,
muscle, and liver of HFD-fed mice. Moreover, p38 MAPK
phosphorylation is increased in WAT and mature white
adipocytes of eNOS knockout compared with wild-type
mice, and ACEA is unable to further increase p38 MAPK
phosphorylation in primary adipocytes obtained from
eNOS
/ mice. This inability of ACEA was accompanied
by the lack of further inhibitory effects on the already
downregulated mitochondrial biogenesis in adipocytes
from eNOS
/ mice. These ﬁndings support the notion
that p38 MAPK may be a potential antiobesity target, as
suggested by others (45,46). Taken together, our data
demonstrate that the ACEA-mediated eNOS decrease re-
sults in sustained activation of p38 MAPK, which may
serve as a negative transcriptional regulator of PGC-1
and downstream mitochondrial gene expression, in adipo-
cytes. AMPK, another enzyme central to cellular bioener-
getics (7), was reported to increase eNOS activity (6),
which is consistent with the observation that CB1 block-
ade activates AMPK (14). We showed here that AMPK
activity, measured as Thr172 phosphorylation, was re-
duced in the metabolically active tissues of ACEA-treated
HFD mice. The clinical implications of our results would
be strengthened by altering eNOS, p38 MAPK, and/or
AMPK pathways in HFD mice to assess possible improve-
ment of mitochondrial biogenesis and reduction of weight
gain.
It is interesting that basal p38 MAPK phosphorylation is
increased in adipocytes from type 2 diabetic subjects in
association with decreased insulin receptor substrate-1
and GLUT4 content (47). In addition, high-fat feeding in
rats increases p38 MAPK phosphorylation in heart (48),
and p38 activation is associated with hepatic insulin
resistance (49). Also, in view of the present data, the fact
that a HFD enhances p38 MAPK phosphorylation in the
heart might be due to endocannabinoid overactivity. In
fact, heart endocannabinoid levels are elevated with two
different types of HFD in mice (50). Thus, our ﬁndings
support the notion that impaired mitochondrial biogenesis
contributes to obesity and related metabolic disorders and
might help in the design of innovative drugs to selectively
counteract the cannabinoid system overactivity in periph-
eral tissues of obese/diabetic patients.
ACKNOWLEDGMENTS
This work was supported by grants from the Ministero
della Salute (to E.N. and M.O.C.) and the Coﬁnanziamento
2007 Programmi di Ricerca Scientiﬁca di Rilevante Inter-
esse Nazionale from the Ministero dell’Istruzione,
dell’Universita ` e della Ricerca (to E.N., M.O.C., and R.V.).
No potential conﬂicts of interest relevant to this article
were reported.
L.T. designed and performed the bulk of the experi-
ments, analyzed all data, and wrote a ﬁrst draft of the
manuscript. A.V. contributed to the analysis of in vitro and
in vivo data and assisted with writing. M.D. contributed to
in vitro studies. A.C. contributed to in vivo studies. M.R.
contributed to the in vitro studies. C.P. contributed to in
vivo studies. U.P., M.O.C., and R.V. contributed to the
analysis of in vivo data and revised the manuscript. E.N.
developed the hypothesis, designed and analyzed all data,
wrote the manuscript, and supervised the project and the
peer review process.
REFERENCES
1. Patti ME, Corvera S. The role of mitochondria in the pathogenesis of type
2 diabetes. Endocr Rev 2010;31:364–395
2. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R,
Valerio A, Francolini M, Moncada S, Carruba MO. Mitochondrial biogene-
sis in mammals: the role of endogenous nitric oxide. Science 2003;299:
896–899
3. Nisoli E, Falcone S, Tonello C, Cozzi V, Palomba L, Fiorani M, Pisconti A,
Brunelli S, Cardile A, Francolini M, Cantoni O, Carruba MO, Moncada S,
Clementi E. Mitochondrial biogenesis by NO yields functionally active
mitochondria in mammals. Proc Natl Acad SciUSA2004;101:16507–16512
4. Wenzel S, Rohde C, Wingerning S, Roth J, Kojda G, Schlu ¨ter KD. Lack of
endothelial nitric oxide synthase-derived nitric oxide formation favors
hypertrophy in adult ventricular cardiomyocytes. Hypertension 2007;49:
193–200
5. Crunkhorn S, Dearie F, Mantzoros C, Gami H, da Silva WS, Espinoza D,
Faucette R, Barry K, Bianco AC, Patti ME. Peroxisome proliferator
activator receptor  coactivator-1 expression is reduced in obesity: poten-
tial pathogenic role of saturated fatty acids and p38 mitogen-activated
protein kinase activation. J Biol Chem 2007;282:15439–15450
25 
27 
29 
31 
33 
35 
37  A
12  13  14 
Age (weeks)  
10  11 
B
o
d
y
 
w
e
i
g
h
t
 
(
g
)
 
0 
100 
200 
A
d
i
p
o
s
i
t
y
 
B 
0 
C
u
m
u
l
a
t
i
v
e
 
f
o
o
d
 
i
n
t
a
k
e
 
(
g
)
 
0 
5 
10 
F
e
e
d
 
e
f
f
i
c
i
e
n
c
y
 
(
w
e
i
g
h
t
 
g
a
i
n
 
/
 
f
o
o
d
 
i
n
t
a
k
e
)
 
x
 
1
0
0
 
100 
200 
300 
400 
C  D 
Veh 
Veh 
Veh 
veh 
ACEA 
HFD 
**  
† 
* 
† 
veh 
ACEA 
HFD 
veh 
ACEA 
HFD 
150 
250 
50 
*  * 
* 
ACEA 
Chow  
ACEA 
Chow 
ACEA 
Chow 
FIG. 7. CB1 receptor stimulation increases body weight in obese mice.
A: Body weight of ACEA- or vehicle-treated mice on a HFD compared
with vehicle-treated mice on a chow regular diet (n  10 animals per
group; *P < 0.05 vs. vehicle-treated mice on a HFD). E, chow plus
vehicle; F, chow plus ACEA; , HFD plus vehicle; f, HFD plus ACEA.
B–D: Adiposity (expressed as percentage of weight of visceral and
subcutaneous fat when value of vehicle (Veh)-treated mice on chow
regular diet is 100), cumulative food intake, and feed efﬁciency (n  8
animals per group; *P < 0.05 **P < 0.01 vs. vehicle-treated mice on a
chow regular diet and †P < 0.05 vs. vehicle-treated mice on a HFD).
CB1 RECEPTORS AND MITOCHONDRIAL BIOGENESIS
2834 DIABETES, VOL. 59, NOVEMBER 2010 diabetes.diabetesjournals.org6. Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP. Direct
activation of AMP-activated protein kinase stimulates nitric-oxide synthe-
sis in human aortic endothelial cells. J Biol Chem 2003;278:31629–31639
7. Canto ´ C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott
PJ, Puigserver P, Auwerx J. AMPK regulates energy expenditure by
modulating NAD
 metabolism and SIRT1 activity. Nature 2009;458:1056–
1060
8. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of
the endocannabinoid system in endocrine regulation and energy balance.
Endocr Rev 2006;27:73–100
9. Cota D, Marsicano G, Tschoep M, Grubler Y, Flachskamm C, Schubert M,
Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F,
Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U.
The endogenous cannabinoid system affects energy balance via central
orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423–431
10. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie ´ P. CB1
cannabinoid receptor knockout in mice leads to leanness, resistance to
diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat
Metab Disord 2004;28:640–648
11. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand
JP, Soubrie ´ P. Anti-obesity effect of SR141716, a CB1 receptor antagonist,
in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol
2003;284:R345–R353
12. Jourdan T, Djaouti L, Demizieux L, Gresti J, Verge `s B, Degrace P. CB1
antagonism exerts speciﬁc molecular effects on visceral and subcutaneous
fat and reverses liver steatosis in diet-induced obese mice. Diabetes
2010;59:926–934
13. Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, Alberobello AT,
D’Esposito V, Beguinot F, Formisano P, Bifulco M. The cannabinoid CB1
receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skel-
etal muscle cells by regulating the expression of phosphatidylinositol-3-
kinase. Mol Pharmacol 2008;74:1678–1686
14. Tedesco L, Valerio A, Cervino C, Cardile A, Pagano C, Vettor R, Pasquali R,
Carruba MO, Marsicano G, Lutz B, Pagotto U, Nisoli E. Cannabinoid type
1 receptor blockade promotes mitochondrial biogenesis through endothe-
lial nitric oxide synthase expression in white adipocytes. Diabetes 2008;
57:2028–2036
15. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C,
Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U,
Monteleone P, Di Marzo V. Regulation, function, and dysregulation of
endocannabinoids in models of adipose and -pancreatic cells and in
obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91:3171–3180
16. Di Marzo V. The endocannabinoid system: its general strategy of action,
tools for its pharmacological manipulation and potential therapeutic
exploitation. Pharmacol Res 2009;60:77–84
17. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman
PA, Sessa WC, Smithies O. Elevated blood pressures in mice lacking
endothelial nitric oxide synthase. Proc Natl Acad SciUSA1996;93:13176–
13181
18. Are ´valo-Martín A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Thera-
peutic action of cannabinoids in a murine model of multiple sclerosis.
J Neurosci 2003;23:2511–2516
19. McClain DA, Hazel M, Parker G, Cooksey RC. Adipocytes with increased
hexosamine ﬂux exhibit insulin resistance, increased glucose uptake, and
increased synthesis and storage of lipid. Am J Physiol Endocrinol Metab
2005;288:E973–E979
20. Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial
biogenesis and function. Physiol Rev 2008;88:611–638
21. Bennetzen MF, Nielsen TS, Paulsen SK, Bendix J, Fisker S, Jessen N, Lund
S, Richelsen B, Pedersen SB. Reduced cannabinoid receptor 1 protein in
subcutaneous adipose tissue of obese. Eur J Clin Invest 2010;40:121–126
22. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K,
Rizzuto R, Bernante P, Federspil G, Vettor R. The endogenous cannabinoid
system stimulates glucose uptake in human fat cells via phosphatidylino-
sitol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol
Metab 2007;92:4810–4819
23. Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM. Modu-
lation of trigeminal sensory neuron activity by the dual cannabinoid-
vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-
2-chloroethylamide. Br J Pharmacol 2004;141:1118–1130
24. Zhang LL, Yan Liu D, Ma LQ, Luo ZD, Cao TB, Zhong J, Yan ZC, Wang LJ,
Zhao ZG, Zhu SJ, Schrader M, Thilo F, Zhu ZM, Tepel M. Activation of
transient receptor potential vanilloid type-1 channel prevents adipogenesis
and obesity. Circ Res 2007;100:1063–1070
25. Ptasinska A, Wang S, Zhang J, Wesley RA, Danner RL. Nitric oxide
activation of peroxisome proliferator-activated receptor  through a p38
MAPK signaling pathway. FASEB J 2007;21:950–961
26. Turu G, Hunyady L. Signal transduction of the CB1 cannabinoid receptor.
J Mol Endocrinol 2010;44:75–85
27. Valerio A, Cardile A, Cozzi V, Bracale R, Tedesco L, Pisconti A, Palomba L,
Cantoni O, Clementi E, Moncada S, Carruba MO, Nisoli E. TNF- down-
regulates eNOS expression and mitochondrial biogenesis in fat and muscle
of obese rodents. J Clin Invest 2006;116:2791–2798
28. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in
rat limbic forebrain and hypothalamus in relation to fasting, feeding and
satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol
2002;136:550–557
29. Blu ¨her M, Engeli S, Klo ¨ting N, Berndt J, Fasshauer M, Ba ´tkai S, Pacher P,
Scho ¨n MR, Jordan J, Stumvoll M. Dysregulation of the peripheral and
adipose tissue endocannabinoid system in human abdominal obesity.
Diabetes 2006;55:3053–3060
30. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Ba ´tkai S,
Harvey-White J, Mackie K, Offerta ´ler L, Wang L, Kunos G. Endocannabi-
noid activation at hepatic CB1 receptors stimulates fatty acid synthesis
and contributes to diet-induced obesity. J Clin Invest 2005;115:1298–
1305
31. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, Di
Marzo V. Endocannabinoid dysregulation in the pancreas and adipose
tissue of mice fed with a high-fat diet. Obesity 2008;16:553–565
32. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E,
Matthaei S, Schick F, Claussen CD, Ha ¨ring HU. Association of increased
intramyocellular lipid content with insulin resistance in lean nondiabetic
offspring of type 2 diabetic subjects. Diabetes 1999;48:1113–1119
33. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy
balance. Nat Neurosci 2005;8:585–589
34. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes.
Diabetologia 2008;51:1356–1367
35. Di Marzo V, Co ˆte ´ M, Matias I, Lemieux I, Arsenault BJ, Cartier A, Piscitelli
F, Petrosino S, Alme ´ras N, Despre ´s JP. Changes in plasma endocannabi-
noid levels in viscerally obese men following a 1 year lifestyle modiﬁcation
programme and waist circumference reduction: associations with changes
in metabolic risk factors. Diabetologia 2009;52:213–217
36. Di Marzo V, Despre ´s JP. CB1 antagonists for obesity–what lessons have we
learned from rimonabant? Nat Rev Endocrinol 2009;5:633–638
37. Bartova A, Birmingham MK. Effect of 
9-tetrahydrocannabinol on mito-
chondrial NADH-oxidase activity. J Biol Chem 1976;251:5002–5006
38. Chiu P, Karler R, Craven C, Olsen DM, Turkanis SA. The inﬂuence of

9-tetrahydrocannabinol, cannabinol and cannabidiol on tissue oxygen
consumption. Res Commun Chem Pathol Pharmacol 1975;12:267–286
39. Mustelin L, Pietila ¨inen KH, Rissanen A, Sovija ¨rvi AR, Piirila ¨ P, Naukkari-
nen J, Peltonen L, Kaprio J, Yki-Ja ¨rvinen H. Acquired obesity and poor
physical ﬁtness impair expression of genes of mitochondrial oxidative
phosphorylation in monozygotic twins discordant for obesity. Am J
Physiol Endocrinol Metab 2008;295:E148–E154
40. Karaliota S, Siafaka-Kapadai A, Gontinou C, Psarra K, Mavri-Vavayanni M.
Anandamide increases the differentiation of rat adipocytes and causes
PPAR and CB1 receptor upregulation. Obesity 2009;17:1830–1838
41. Hillard CJ, Jarrahian A. Cellular accumulation of anandamide: consensus
and controversy. Br J Pharmacol 2003;140:802–808
42. Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P.
Anandamide induced PPAR transcriptional activation and 3T3–L1 pre-
adipocyte differentiation. Eur J Pharmacol 2005;517:174–181
43. Athanasiou A, Clarke AB, Turner AE, Kumaran NM, Vakilpour S, Smith
PA, Bagiokou D, Bradshaw TD, Westwell AD, Fang L, Lobo DN,
Constantinescu CS, Calabrese V, Loesch A, Alexander SP, Clothier RH,
Kendall DA, Bates TE. Cannabinoid receptor agonists are mitochondrial
inhibitors: a uniﬁed hypothesis of how cannabinoids modulate mito-
chondrial function and induce cell death. Biochem Biophys Res Com-
mun 2007;364:131–137
44. Maccarrone M, Bari M, Lorenzon T, Bisogno T, Di Marzo V, Finazzi-Agro `A .
Anandamide uptake by human endothelial cells and its regulation by nitric
oxide. J Biol Chem 2000;275:13484–13492
45. Robidoux J, Cao W, Quan H, Daniel KW, Moukdar F, Bai X, Floering LM,
Collins S. Selective activation of mitogen-activated protein (MAP) kinase
kinase 3 and p38 MAP kinase is essential for cyclic AMP-dependent UCP1
expression in adipocytes. Mol Cell Biol 2005;25:5466–5479
46. Maekawa T, Jin W, Ishii S. The role of ATF-2 family transcription factors
in adipocyte differentiation: anti-obesity effects of p38 inhibitors. Mol Cell
Biol 2010;30:613–625
47. Carlson CJ, Koterski S, Sciotti RJ, Poccard GB, Rondinone CM. Enhanced
basal activation of mitogen-activated protein kinases in adipocytes from
type 2 diabetes: potential role of p38 in the downregulation of GLUT4
expression. Diabetes 2003;52:634–641
L. TEDESCO AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, NOVEMBER 2010 283548. Li SY, Liu Y, Sigmon VK, McCort A, Ren J. High-fat diet enhances visceral
advanced glycation end products, nuclear O-Glc-Nac modiﬁcation, p38
mitogen-activated protein kinase activation and apoptosis. Diabetes Obes
Metab 2005;7:448–454
49. Liu HY, Collins QF, Xiong Y, Moukdar F, Lupo EG Jr, Liu Z, Cao W.
Prolonged treatment of primary hepatocytes with oleate induces insulin
resistance through p38 mitogen-activated protein kinase. J Biol Chem
2007;282:14205–14212
50. Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, Di Marzo V.
Dysregulation of peripheral endocannabinoid levels in hyperglycemia
and obesity: effect of high fat diets. Mol Cell Endocrinol 2008;286:S66–
S78
CB1 RECEPTORS AND MITOCHONDRIAL BIOGENESIS
2836 DIABETES, VOL. 59, NOVEMBER 2010 diabetes.diabetesjournals.org